Punctate Palmoplantar Keratoderma Type 1
2 clinical trials · Condition
◉ Watch Punctate Palmoplantar Keratoderma Type 1
| Record | Firm | Date |
|---|---|---|
| Study Designed to Evaluate Safety and Efficacy of 1% Topical Formulation of KM-001 on Type 1 Punctate Palmoplantar Keratoderma or Pachyonychia Congenita Diseases (NCT05435638) | Orvida Pharma (formerly Kamari Pharma) | 2022-07-17 |
Track Punctate Palmoplantar Keratoderma Type 1 automatically
Every clearance here is in the API, with alerts when new ones post.